2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1315

Influence of Rheumatoid Arthritis and Axial Spondyloarthritis on Pregnancy Complications, Pregnancy Outcome and Delivery Mode
Abstract Number: 1039

Influences for Therapeutic Changes in Rheumatoid Arthritis Patients from the Veterans Affairs Rheumatology Arthritis Registry Who Have Moderate to High Disease Activity
Abstract Number: 1705

Inhibition of EZH2 Stops Fibrosis and Improves Angiogenesis in Scleroderma
Abstract Number: 956

Inhibition of Fucosylation in Endothelial Cells Reduces Rheumatoid Arthritis Angiogenesis
Abstract Number: 1714

Inhibition of Hedgehog Acyltransferase Alleviates the Profibrotic Effects of Transforming Growth Factor β in Systemic Sclerosis
Abstract Number: 2564

Inhibition of Neutrophil Elastase Protects Against Glomerulonephritis and Thrombosis in a Mouse Model of Lupus
Abstract Number: 2970

Inhibition of Radiographic Progression in Psoriatic Arthritis By Adalimumab Independent of the Control of Clinical Disease Activity
Abstract Number: 2562

Inhibition of Spleen Tyrosine Kinase Improves Renal Pathology and Reduces Lymphocyte Activation in the MRL/Lpr and NZB/NZW Murine Models of Systemic Lupus Erythematosus
Abstract Number: 1321

Inhibition of the Mechanistic Target of Rapamycin Pathway and Glutaminolysis Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Synergistically Ameliorates Arthritis in SKG Mice
Abstract Number: 1078

Initial Combination Therapy Versus Step-up Therapy Is More Effective and Less Costly As a Treat to Target Strategy for RA: A Markov Model Based upon the Dutch Rheumatoid Arthritis Monitoring Registry Cohorts
Abstract Number: 1188

Initial Estimates of Efficacy of Intra-Articular 2.5% Polyacrylamide Hydrogel for the Treatment of Knee Osteoarthritis: An Observational Proof-of-Concept Study
Abstract Number: 2091

Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies
Abstract Number: 1141

Initial Results of a Clinical Study to Determine Whether a Tolerizing Regimen of Pegloticase Can Increase the Frequency of Subjects Having Sustained Lowering of Serum Urate
Abstract Number: 2252

Initial Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) in Children with Juvenile Myositis
Abstract Number: 1144

Initiating Colchicine and Urate-Lowering Therapy Reduces Baseline Inflammation, and Improves Vascular Endothelial but Not Smooth Muscle Function in Gout Subjects: Resistance to Endothelial Improvement Among Patients with Cardiovascular Comorbidities

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].